Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Related Citations for PubMed (Select 22753324)

1.

Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol.

Ahmed TA, Ibrahim HM, Ibrahim F, Samy AM, Kaseem A, Nutan MT, Hussain MD.

J Pharm Sci. 2012 Oct;101(10):3753-62. doi: 10.1002/jps.23250. Epub 2012 Jun 29.

PMID:
22753324
2.

A novel in situ forming drug delivery system for controlled parenteral drug delivery.

Kranz H, Bodmeier R.

Int J Pharm. 2007 Mar 6;332(1-2):107-14. Epub 2006 Sep 26.

PMID:
17084049
3.

Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.

Kranz H, Bodmeier R.

Eur J Pharm Sci. 2008 Jul 3;34(2-3):164-72. doi: 10.1016/j.ejps.2008.03.004. Epub 2008 Apr 8.

PMID:
18501569
4.

Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.

Ahmed TA, Ibrahim HM, Samy AM, Kaseem A, Nutan MT, Hussain MD.

AAPS PharmSciTech. 2014 Jun;15(3):772-80. doi: 10.1208/s12249-014-0101-3. Epub 2014 Mar 20.

5.

Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems.

Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R.

Int J Pharm. 2001 Jan 5;212(1):11-8.

PMID:
11165816
6.

Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.

Dong WY, Körber M, López Esguerra V, Bodmeier R.

J Control Release. 2006 Oct 10;115(2):158-67. Epub 2006 Jul 20.

PMID:
16963145
7.

Monitoring release of ketoprofen enantiomers from biodegradable poly(D,L-lactide-co-glycolide) injectable implants.

Wang SH, Liang ZH, Zeng S.

Int J Pharm. 2007 Jun 7;337(1-2):102-8. Epub 2006 Dec 28.

PMID:
17296274
8.

Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.

Luan X, Bodmeier R.

J Control Release. 2006 Jan 10;110(2):266-72. Epub 2005 Nov 21.

PMID:
16300851
9.

In situ micro-sized gel-forming injectable implant using biodegradable amphiphilic graft copolymer.

Cho KY, Lee S, Park JK.

Macromol Biosci. 2007 Jun 7;7(6):784-8.

PMID:
17541923
10.

Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables.

Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH.

Eur J Pharm Biopharm. 2000 Sep;50(2):257-62.

PMID:
10962236
11.

PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.

Parent M, Nouvel C, Koerber M, Sapin A, Maincent P, Boudier A.

J Control Release. 2013 Nov 28;172(1):292-304. doi: 10.1016/j.jconrel.2013.08.024. Epub 2013 Sep 1. Review.

PMID:
24001947
12.

In vitro and in vivo drug release from a novel in situ forming drug delivery system.

Kranz H, Yilmaz E, Brazeau GA, Bodmeier R.

Pharm Res. 2008 Jun;25(6):1347-54.

PMID:
17968634
13.

NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability.

Péan JM, Venier-Julienne MC, Boury F, Menei P, Denizot B, Benoit JP.

J Control Release. 1998 Dec 4;56(1-3):175-87.

PMID:
9801441
14.

Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.

Solorio L, Olear AM, Hamilton JI, Patel RB, Beiswenger AC, Wallace JE, Zhou H, Exner AA.

Theranostics. 2012;2(11):1064-77. doi: 10.7150/thno.4181. Epub 2012 Nov 8.

15.

Structure formation in injectable poly(lactide-co-glycolide) depots.

Wang L, Kleiner L, Venkatraman S.

J Control Release. 2003 Jul 31;90(3):345-54.

PMID:
12880701
16.

In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer.

Asmus LR, Tille JC, Kaufmann B, Melander L, Weiss T, Vessman K, Koechling W, Schwach G, Gurny R, Möller M.

J Control Release. 2013 Feb 10;165(3):199-206. doi: 10.1016/j.jconrel.2012.11.014. Epub 2012 Dec 3.

PMID:
23220105
17.

Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.

Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN.

J Control Release. 2007 May 14;119(1):77-85. Epub 2007 Feb 3.

PMID:
17349712
18.

Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?

Parent M, Boudier A, Dupuis F, Nouvel C, Sapin A, Lartaud I, Six JL, Leroy P, Maincent P.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):640-9. doi: 10.1016/j.ejpb.2013.08.005. Epub 2013 Aug 13.

PMID:
23954508
19.

Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist.

Du L, Cheng J, Chi Q, Qie J, Liu Y, Mei X.

Chem Pharm Bull (Tokyo). 2006 Sep;54(9):1259-65.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk